There were three posters from the ABCD audit programme presented at the Diabetes UK annual professional conference at SEC, Glasgow, 26-28 February 2025.
In a poster from the Worldwide Audit of Testosterone Deficiency in Men with Type 2 Diabetes, Prof Hugh Jones showed that testosterone replacement therapy (TRT) improved symptoms and quality of life increasingly over at least 24 months. TRT also reduced HbA1c increasingly over a three year follow up period.
In a poster using data from both the semaglutide and oral semaglutide audits, Dr Su Khin showed that both oral and injectable versions experienced a reduction in HbA1c, but the reduction was greater with the injectable version. She concluded that the findings support personalized treatment choices based on individual preferences and ability to comply to oral ingestion instructions to ensure optimal absorption of the oral formulation.
In a poster from the ABCD worldwide EndoBarrier registry which now has data on 1101 EndoBarrier treated patients, Dr Bob Ryder presented an analysis comparing data after 6-months of EndoBarrier treatment with the full 12-months. Whilst weight and HbA1c both fell significantly between 6-months and 12-months, the analysis suggested that most of benefits of EndoBarrier on weight and HbA1c are achieved in 6‐months. In the full registry, 46/1101 (4.2%) experienced serious adverse events (SAE). 20/46 (43.5%) SAE would have been avoided by removal at 6 months. It was particularly noteworthy that 11/13(85%) liver abscess SAE would have been avoided by removal at 6 months. EndoBarrier, now named RESET®, is expected to regain its CE mark imminently and is going to be re-launched with a maximum recommended implantation time of 9-months.
